Category: Carbapenem

July 13, 2016 davidzamorano

Li JQ, Tang CQ, Wang H, Ji SZ, Lü KY, Xiao SC, Deng AM, Huang Y, Xia ZF   Abstract   OBJECTIVE: To evaluate the impact of extended-spectrum β-lactamase (ESBL) on clinical outcome and medical cost in patients with bloodstream infection (BSI) due to Klebsiella pneumoniae.   METHODS: A retrospective study was conducted in patients admitted into Changhai Hospital between January 2013 and…

July 12, 2016 davidzamorano

Thaden JT, Pogue JM, Kaye KS   Abstract Antimicrobial resistance has been identified by the World Health Organization as “one of the three greatest threats to human health.” Gram negative bacteria in particular drive this alarming trend. Carbapenem-resistant Enterobacteriaceae (CRE) such as Escherichia coli, Klebsiella pneumoniae, and Enterobacter species are of particular importance as they are associated…

July 11, 2016 davidzamorano

Strawbridge S, Nailor MD   Abstract   BACKGROUND: High doses of β-lactam antibiotics have been advocated for acute pulmonary exacerbations caused by Pseudomonas aeruginosa in patients with cystic fibrosis (CF) secondary to high minimum inhibitory concentrations (MIC) of the infecting organisms. Some β-lactam antibiotics have increased elimination in CF patients. This case series examines the safety…

July 10, 2016 davidzamorano

Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA.   The carbapenems are beta-lactam antimicrobial agents with an exceptionally broad spectrum of activity. Older carbapenems, such as imipenem, were often susceptible to degradation by the enzyme dehydropeptidase-1 (DHP-1) located in renal tubules and required co-administration with a DHP-1 inhibitor such as cilastatin. Later additions to…